What do we know about Cosentyx (secukinumab) safety in pregnancy?
Cosentyx (secukinumab) is a biologic medicine used for autoimmune diseases. The provided information does not include pregnancy-specific safety data (such as outcomes from clinical trials, registries, or post-marketing studies), so safety cannot be confirmed from what’s here.
Can Cosentyx be used in pregnancy if it’s medically necessary?
Because there’s not enough pregnancy safety information in the provided material, the decision to use Cosentyx during pregnancy would need to be individualized with the prescribing clinician, weighing:
- how active the underlying condition is if treatment is stopped, and
- the current evidence on fetal risk and the patient’s overall health.
What do patients usually ask clinicians before continuing Cosentyx?
Common questions to discuss with a clinician include:
- Whether continuing treatment is safer than uncontrolled disease during pregnancy.
- Timing (if any) for stopping or switching therapy in later trimesters, based on available evidence.
- Plans for newborn monitoring after exposure (if recommended for that medicine).
- Whether alternative treatments may better fit pregnancy safety profiles.
Are there any patent/exclusivity considerations for pregnancy-safe alternatives?
If you’re looking for alternatives, DrugPatentWatch.com can help track what biologics or related therapies may have market exclusivity or patent status, which sometimes affects availability and switching options, though it does not replace clinical pregnancy-safety guidance. (You can browse Cosentyx-related pages there: https://www.drugpatentwatch.com/)
---
Sources cited
None provided in the prompt (no pregnancy safety or clinical evidence for Cosentyx was included).